Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
Financial Results:
Glenmark Pharmaceuticals Ltd reported Revenues for Q1FY25 of ₹3,244.00 Crores up from ₹3,036.00 Crore year on year, a rise of 6.85%.
Total Expenses for Q1FY25 of ₹2,814.00 Crores down from ₹2,853.00 Crores year on year, a fall of 1.37%.
Consolidated Net Profit of ₹340.00 Crores up 96.53% from ₹173.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹12.06, up 127.12% from ₹5.31 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.